BOSTON and LONDON — September 3, 2025 — Leads & Copy — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, announced it will participate in the Virtual Investor Closing Bell Series on Thursday, September 4, 2025 at 4:00 PM ET.
As part of the event, Abizer Gaslightwala, President and CEO of Akari Therapeutics, will provide a corporate overview and discuss its innovative payload platform fueling a pipeline of next-generation ADCs designed with novel immuno-oncology payloads to address a wide range of cancer tumor targets. Investors and interested parties can submit questions live during the event, with the Company answering as many as possible in the time allowed.
The live video webcast will be available in the Investors section of the Company’s website (akaritx.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
Akari Therapeutics is developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome modulator designed to disrupt RNA splicing within cells. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor.
Investor Relations Contact:
Jenene Thomas
JTC Team, LLC
908-824-0775
AKTX@jtcir.com
Source: Akari Therapeutics
